{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "SEK", "esgPopulated": false, "market": "gb_market", "longName": "Hansa Biopharma AB (publ)", "marketState": "CLOSED", "regularMarketPrice": 53.75, "exchange": "CXE", "shortName": "Hansa Biopharma AB", "exchangeTimezoneShortName": "BST", "exchangeTimezoneName": "Europe/London", "regularMarketChangePercent": 0.0, "gmtOffSetMilliseconds": 3600000, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "53.75 - 53.75", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "fiftyTwoWeekLow": 53.75, "fiftyTwoWeekHigh": 53.75, "earningsTimestamp": 1689850740, "earningsTimestampStart": 1689850740, "earningsTimestampEnd": 1689850740, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -14.28, "firstTradeDateMilliseconds": 1683615600000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683622882, "regularMarketDayHigh": 53.75, "regularMarketDayRange": "53.75 - 53.75", "regularMarketDayLow": 53.75, "regularMarketVolume": 1, "regularMarketPreviousClose": 53.75, "bid": 53.65, "ask": 0.0, "fullExchangeName": "Cboe UK", "financialCurrency": "SEK", "regularMarketOpen": 53.75, "averageDailyVolume3Month": 1, "averageDailyVolume10Day": 1, "bookValue": 7.907, "fiftyDayAverage": 53.75, "fiftyDayAverageChange": 0.0, "fiftyDayAverageChangePercent": 0.0, "twoHundredDayAverage": 53.75, "twoHundredDayAverageChange": 0.0, "twoHundredDayAverageChangePercent": 0.0, "priceToBook": 6.797774, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "symbol": "HNSAS.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "ScheelevAegen 22", "city": "Lund", "zip": "223 63", "country": "Sweden", "phone": "46 46 16 56 70", "website": "https://www.hansabiopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.", "fullTimeEmployees": 159, "companyOfficers": [{"maxAge": 1, "name": "Mr. S\u00f8ren  Tulstrup M.Sc", "age": 57, "title": "Pres & CEO", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 15258000, "fmt": "15.26M", "longFmt": "15,258,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Donato  Spota", "age": 51, "title": "CFO & Sr. VP", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Christian  Kjellman", "age": 55, "title": "Sr. VP, Chief Scientific Officer & COO", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Eva-Maria  Joed", "age": 53, "title": "VP of Fin. & Admin.", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Klaus  Sindahl", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anne S\u00e4fstr\u00f6m Lanner", "age": 53, "title": "Sr. VP & Chief HR Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Emanuel  Bj\u00f6rne", "age": 49, "title": "VP & Head of Bus. Devel.", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lena  Winstedt", "age": 53, "title": "Head of Science", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Vincenza  Nigro M.B.A.", "title": "VP & Head of Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Achim  Kaufhold M.D., Ph.D.", "age": 64, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1958, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}